On October 30, 2025, the First International Jewelry Fashion Theme Month and the 2025 Shanghai Haute Couture Week officially kicked off in the Grand Yuyuan Cultural Area. As the first major event following the establishment of the Shanghai International Jewelry & Style District, this inaugural theme month not only brings a series of exciting activities but also marks a new chapter in the development of the functional district.

Hong Kong, October 28, 2025 -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, today announced its business update for the third quarter of 2025, highlighting solid revenue growth and accelerated momentum across core product segments and key markets.

(October 28, 2025, Shanghai, China)– On October 28, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced its financial results for the first three quarters of 2025.

Recently, during the 63rd Annual Meeting of the Japan Society of Clinical Oncology (JSCO), Henlius successfully hosted the “Bridging Horizons · Henlius Japan Reception 2025” expert exchange symposium in Yokohama, Japan.

Shanghai, China, October 22, 2025 – Shanghai Henlius Biotech, Inc. (2696.HK) announced that its independently developed innovative anti-PD-1 mAb serplulimab (trade name in Europe: Hetronifly^®) has successfully completed enrolment of all 200 patients in the U.S. bridging clinical study (ASTRIDE) comparing serplulimab plus chemotherapy with atezolizumab plus chemotherapy in previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC). This milestone paves the way for Henlius to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).

Shanghai, China, October 20, 2025 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX43, the company's innovative programmed death-ligand 1 (PD-L1) targeting antibody-drug conjugate (ADC), for the treatment of thymic epithelial tumors (TETs).

On 16 October, the 2025 Sustainability Global Leaders Conference was held in Shanghai. Themed “Joining Hands to Address Challenges: Global Action, Innovation, and Sustainable Growth”, the Conference brought together approximately 500 guests from China and abroad, including Nobel Prize laureates, Turing Award laureates, as well as executives from Global 500 companies.

On 12 October 2025, Fosun International Limited (“Fosun International”) and BNP Paribas have signed a strategic cooperation agreement (“Agreement”), committing to collaborate closely in support of Fosun International and its subsidiaries’ (collectively as “Fosun”) future development strategies.

Shanghai, China, October 9, 2025 — Shanghai Henlius Biotech, Inc. (2696.HK) announced that its self-developed innovative anti-PD-1 monoclonal antibody, HANSIZHUANG (serplulimab, Hetronifly^® in Europe), in combination with chemotherapy for the neoadjuvant/adjuvant monotherapy treatment of gastric cancer, has met the primary endpoint of Event-Free Survival (EFS) in an interim analysis of its phase 3 clinical study (ASTRUM-006). This outcome represents a breakthrough, making it the world-first regimen to replace adjuvant chemotherapy with mono-immunotherapy in the perioperative treatment of gastric cancer.